Optimization protocol for amyloid-β peptides detection in human cerebrospinal fluid using SELDI TOF MS.
about
Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applicationsA window into the heterogeneity of human cerebrospinal fluid Aβ peptidesExpression of A2V-mutated Aβ in Caenorhabditis elegans results in oligomer formation and toxicity.Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides.Thin-layer matrix sublimation with vapor-sorption induced co-crystallization for sensitive and reproducible SAMDI-TOF MS analysis of protein biosensors.Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementiaMicroglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles.Cerebrospinal fluid biomarkers for Alzheimer's disease: the present and the future.Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.Proteomics as an innovative tool to investigate frontotemporal disorders.Calcium enhances binding of Aβ monomer to DMPC lipid bilayer.Conformational targeting of intracellular Aβ oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum.Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia.Mirror Image of the Amyloid-β Species in Cerebrospinal Fluid and Cerebral Amyloid in Alzheimer's Disease.Molecular subtypes of Alzheimer's disease.Evolving Relevance of Neuroproteomics in Alzheimer's Disease.Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimer's disease.
P2860
Q26995267-007D94E9-F25C-40E7-97AD-00368B00722EQ27010785-9D2AC057-0C92-41CB-B369-FA1A4EFBF5B9Q33797442-9F3FBE61-8C37-48D4-917A-AB2539CE3064Q34244772-ACA7A840-618B-4FE7-9FB3-C161326A7C54Q34357363-79D32280-E637-4EBF-AA08-B111B94ED1E5Q36708123-4AB05D3F-B61F-42C4-B7CF-78C50EE26140Q37631171-8CF75250-491F-44C4-AE50-5F23053A77C7Q37895052-E1406969-6420-4D90-A3D7-75C89B59F592Q38210117-3EBA8E03-FBAF-494D-BB50-5F7F8BDD221CQ38802995-D2A8832F-E644-4A65-9F70-1A2474E6CB82Q39427596-3B799CA8-AA7F-48D7-9889-010B049CE1AAQ40470312-CD7C02DA-0458-4194-B004-91CC969A1BC7Q45420612-13D46547-91C9-4480-A2F5-C704AD2B5718Q46664885-5BDC9D0A-622A-46E9-81F4-63883C9727DAQ49831229-03945472-2CEE-47F4-945C-9108472F7093Q50999408-EF5A50BE-C94E-48E3-BEBB-DB794E07EE71Q53206626-ED62A585-36EF-40C0-A816-9F5CDF9A04F4
P2860
Optimization protocol for amyloid-β peptides detection in human cerebrospinal fluid using SELDI TOF MS.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Optimization protocol for amyl ...... inal fluid using SELDI TOF MS.
@ast
Optimization protocol for amyl ...... inal fluid using SELDI TOF MS.
@en
type
label
Optimization protocol for amyl ...... inal fluid using SELDI TOF MS.
@ast
Optimization protocol for amyl ...... inal fluid using SELDI TOF MS.
@en
prefLabel
Optimization protocol for amyl ...... inal fluid using SELDI TOF MS.
@ast
Optimization protocol for amyl ...... inal fluid using SELDI TOF MS.
@en
P2093
P50
P356
P1476
Optimization protocol for amyl ...... inal fluid using SELDI TOF MS.
@en
P2093
Anna Bruno
Giuliano Binetti
Simone Lista
Valentina Albertini
P304
P356
10.1002/PRCA.200900166
P577
2010-03-01T00:00:00Z